Stage IIIB Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Back to Stage IIIB Cutaneous Melanoma AJCC v7

Indication	Status	Phase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02965716	Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	Treatment	Pembrolizumab (DB09037) Talimogene laherparepvec (DB13896)
NCT02500576	Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma	Treatment	Aldesleukin (DB00041) Cyclophosphamide (DB00531) Fludarabine (DB01073) Pembrolizumab (DB09037)